Niclosamide [50-65-7]

Catalog number: AG-CR1-3643-G001
Brand: AdipoGen Life Sciences
Packing: 1 g
Other sizes: Other sizes available
Price: € 100.00
Expected delivery time: 7 days
Quantity:
Chemical Structure
Chemical Structure...

Product specifications for - Niclosamide [50-65-7]

Overview: 
Product group: Chemicals
Category: Other
CAS No.: 50-65-7
Properties: 
Purity: >95%
Molecular Formula: C13H8Cl2N2O4
Molecular weight: 327.1
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352200
Storage instructions: 2-¦C to 8-¦C, -20-¦C
Scientific information: 
Scientific info: Antihelminthic, molluscicide and trypanocidal agent that inhibits mitochondrial oxidative phosphorylation and anaerobic ATP production. Anticancer agent with antiproliferative activity in a broad spectrum of cancer cells. Targets and inhibits multiple signaling pathways, including STAT3, NF-kB, Wnt/beta-catenin, Notch and mTORC1. Shown to block TNF-alpha-induced IkappaBalpha phosphorylation, translocation of p65 and the expression of NF-kappaB-regulated genes and elevates reactive oxygen species (ROS) levels. Promotes Frizzled1 internalization, down-regulates the expression of Dishevelled-2 protein and inhibits beta-catenin stabilization. Inhibits mTORC1 but not mTORC2 signaling in cells maintained in nutrient-rich conditions. Cell permeable selective STAT3 inhibitor (IC50=0.25microM). Inhibits the activation, nuclear translocation and transactivation of STAT3. Selective over STAT1, STAT5, JAK1, JAK2 and Src kinases. Induces cell cycle arrest, growth inhibition, autophagy and apoptosis. Inhibits S100A4 (Metastasin-1)-induced metastasis in vivo. Inhibits androgen receptor (AR) splice variants. Anti-inflammatory compound. Quorum sensing inhibitor. Broad range antiviral agent that targets acidified endosomes. Antiobesity and antidiabetic agent. Positive allosteric neuropetide Y4 receptor ligand and increases energy expenditure and lipid metabolism through mitochondrial uncoupling. - Chemical. CAS: 50-65-7. Formula: C13H8Cl2N2O4. MW: 327.1. Antihelminthic, molluscicide and trypanocidal agent that inhibits mitochondrial oxidative phosphorylation and anaerobic ATP production. Anticancer agent with antiproliferative activity in a broad spectrum of cancer cells. Targets and inhibits multiple signaling pathways, including STAT3, NF-kB, Wnt/beta-catenin, Notch and mTORC1. Shown to block TNF-alpha-induced IkappaBalpha phosphorylation, translocation of p65 and the expression of NF-kappaB-regulated genes and elevates reactive oxygen species (ROS) levels. Promotes Frizzled1 internalization, down-regulates the expression of Dishevelled-2 protein and inhibits beta-catenin stabilization. Inhibits mTORC1 but not mTORC2 signaling in cells maintained in nutrient-rich conditions. Cell permeable selective STAT3 inhibitor (IC50=0.25microM). Inhibits the activation, nuclear translocation and transactivation of STAT3. Selective over STAT1, STAT5, JAK1, JAK2 and Src kinases. Induces cell cycle arrest, growth inhibition, autophagy and apoptosis. Inhibits S100A4 (Metastasin-1)-induced metastasis in vivo. Inhibits androgen receptor (AR) splice variants. Anti-inflammatory compound. Quorum sensing inhibitor. Broad range antiviral agent that targets acidified endosomes. Antiobesity and antidiabetic agent. Positive allosteric neuropetide Y4 receptor ligand and increases energy expenditure and lipid metabolism through mitochondrial uncoupling.
Safety information: 
MSDS: MSDS
Hazard information: Non-hazardous, Warning
Additional information: 
Synonyms: AG-CR1-3643-G001; AdipoGen Life Sciences
The effect of sublethal concentrations of the molluscicide niclosamide on the infectivity of Schistosoma mansoni cercariae: A.M. Ghandour & G. Webbe; J. Helminthol. 49, 245 (1975) Read more
In vitro trypanocidal activity of the anti-helminthic drug niclosamide: K. Merschjohann & D. Steverding; Exp. Parasitol. 118, 637 (2008) Read more
The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling: M. Chen, et al.; Biochem. 48, 10267 (2009) Read more
Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling: A.D. Balgi, et al.; PLoS One 4, e7124 (2009) Read more
Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway: X. Ren, et al.; ACS Med. Chem. Lett. 1, 454 (2010) Read more
Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species: Y. Jin, et al.; Cancer Res. 70, 2516 (2010) Read more
Niclosamide: an established antihelminthic drug as a potential therapy against S100A4-mediated metastatic colon tumors: D.M. Helfman; J. Natl. Cancer Inst. 103, 991 (2011) Read more
Niclosamide induces mitochondria fragmentation and promotes both apoptotic and autophagic cell death: S.J. Park, et al.; BMB Rep. 44, 517 (2011) Read more
Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/beta-catenin pathway: W. Lu, et al.; PLoS One 6, e29290 (2011) Read more
Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells: J.X. Pan, et al.; Chin. J. Cancer 31, 178 (2012) (Review) Read more